Holen Sie sich die Stockscreener-App
1.41
7.84%
-0.12
Schlusskurs vom Vortag:
$1.53
Offen:
$1.52
24-Stunden-Volumen:
116.92K
Relative Volume:
0.78
Marktkapitalisierung:
$24.75M
Einnahmen:
$411.00K
Nettoeinkommen (Verlust:
$-4.85M
KGV:
-3.2045
EPS:
-0.44
Netto-Cashflow:
$-4.88M
1W Leistung:
-18.02%
1M Leistung:
+16.53%
6M Leistung:
-55.80%
1J Leistung:
-55.80%
1-Tages-Spanne:
$1.35
$1.545
1-Wochen-Bereich:
$1.35
$1.75
52-Wochen-Spanne:
$1.20
$4.44
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Firmenname
Lexaria Bioscience Corp
Sektor
Branche
Telefon
250-765-6424
Adresse
100 - 740 MCCURDY ROAD, KELOWNA
Vergleichen Sie LEXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
1.41 | 24.75M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully - Yahoo Finance
HighTower Advisors LLC Boosts Holdings in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Completes Enrollment for Pioneering Drug Delivery Study - TipRanks
Lexaria completes enrollment for diabetes drug study - Investing.com
Lexaria completes enrollment for diabetes drug study By Investing.com - Investing.com UK
Lexaria's GLP-1 Study Hits Major Milestone with 20% Higher Patient Enrollment - Stock Titan
Lexaria begins human trial for oral diabetes treatment - Investing.com India
Lexaria begins human trial for oral diabetes treatment By Investing.com - Investing.com South Africa
Lexaria Bioscience Begins Human Trials for Oral Liraglutide Alternative - TipRanks
Lexaria's Human GLP-1 Study #5 Begins Dosing - TradingView
Revolutionary Oral GLP-1 Drug Challenges $1.8B Saxenda Market in New Trial - Stock Titan
Lexaria Bioscience (LEXX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Oral tirzepatide capsules match injection efficacy in Lexaria study By Investing.com - Investing.com South Africa
Lexaria’s Oral Capsules Rival Injectable Weight Loss Treatment - TipRanks
Oral tirzepatide capsules match injection efficacy in Lexaria study - Investing.com
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R) - ACCESS Newswire
Lexaria Bioscience's (LEXX) DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound - StreetInsider.com
Revolutionary Oral Alternative to Zepbound Shows 47% Fewer Side Effects in Clinical Trial - StockTitan
Lexaria Bioscience stock hits 52-week low at $1.37 By Investing.com - Investing.com Australia
Lexaria Bioscience stock hits 52-week low at $1.37 - Investing.com
Lexaria Bioscience Advances Strategy in GLP-1 Drug Sector - TipRanks
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience - TradingView
Could This Small Biotech Solve GLP-1 Drugs' Biggest Problems? Lexaria's Triple Strategy Explained - StockTitan
Lexaria Bioscience Advances GLP-1 Study with New Ethics Approval - TipRanks
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm - TradingView
Can This Small Biotech Transform GLP-1 Drugs From Shots to Pills? Clinical Trial Update - StockTitan
Lexaria Bioscience Targets Breakthrough in Oral Diabetes Medication - TipRanks
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide - WICZ
Can This Small Biotech Revolutionize $30B GLP-1 Market With First-Ever Oral Liraglutide? - StockTitan
Lexaria Bioscience Corp. (NASDAQ:LEXX) Sees Significant Decline in Short Interest - Defense World
Lexaria Bioscience stock hits 52-week low at $1.62 - MSN
Lexaria Secures Two New Patents for Epilepsy Treatment with DehydraTECH - MSN
Lexaria secures new patents for epilepsy treatment tech By Investing.com - Investing.com Nigeria
Lexaria Bioscience stock hits 52-week low at $1.62 By Investing.com - Investing.com South Africa
Lexaria secures new patents for epilepsy treatment tech - MSN
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy - WICZ
Lexaria's Game-Changing Epilepsy Patents Outperform Epidiolex Technology | LEXX - StockTitan
Lexaria Initiates Groundbreaking Biodistribution Study for DehydraTECH GLP-1 - TipRanks
Revolutionary GLP-1 Study: Lexaria's DehydraTECH Goes Head-to-Head with Rybelsus - StockTitan
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway | Users | observernewsonline.com - FinancialContent
Lexaria Advances Human Study on Diabetes and Weight Loss Treatment - TipRanks
Revolutionary GLP-1 Breakthrough: Lexaria's Technology Matches Zepbound Efficacy with Fewer Side Effects - StockTitan
Lexaria reports promising drug delivery study results - Investing.com India
Research Analysts Issue Forecasts for LEXX Q2 Earnings - Defense World
Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024 - TipRanks
Lexaria Releases Annual Letter from the CEO - WICZ
Finanzdaten der Lexaria Bioscience Corp-Aktie (LEXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):